Overview
Investment Type
Venture Capital
Funds raised 2
| Date | Fund size | Announcement |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 23, 2020 | $170M | Pureos Bioventures Closes First Fund with USD 170 Million |
Portfolio 1
| Date | Name | Website | Total Raised | Location |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 31
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 1, 2026 | Ipsen to acquire Memo Therapeutics for up to EUR 700 million | French biopahram company Ipsen and Schlieren-based Memo Therapeutics AG announced today they have entered into a definitive share purchase agreement under which Ipsen has agreed to acquire all issued and outstanding shares of Memo Therapeu... |
| Jan 11, 2025 | AnaCardio's €19 Million Leap: A New Dawn for Heart Failure Treatment | In the world of biopharmaceuticals, every funding round can feel like a heartbeat—vital and pulsating with potential. AnaCardio, a clinical-stage startup based in Stockholm, has just secured €19 million (approximately USD 19 million) to adv... |
| Jan 9, 2025 | AnaCardio raises USD 19 million to advance first-in-class drug candidate AC01 for heart failure | AnaCardio raises USD 19 million to advance first-in-class drug candidate AC01 for heart failure Thu, Jan 09, 2025 09:00 CET Report this content Reports positive results from phase 1b study of AC01 in patients with heart failure and reduced ... |
| Nov 13, 2024 | Alentis Therapeutics Secures $181.4 Million to Pioneer Cancer Treatments | In a bold move to reshape cancer treatment, Alentis Therapeutics has successfully raised $181.4 million in an oversubscribed Series D funding round. This infusion of capital, led by OrbiMed and co-led by Novo Holdings and Jeito Capital, sig... |
| Nov 12, 2024 | Alentis Therapeutics raises $181.4 million in oversubscribed series D round | Normal 0 false false false EN-GB X-NONE AR-SA Besides OrbiMed, Novo Holdings and Jeito Capital, Alentis Therapeutics’ series D round saw the participation of new investors Frazier Life Sciences, Longitude Capital, Catalio Capital, Piper Hea... |
| Nov 2, 2023 | Memo Therapeutics Raises CHF 25 Million Series C Financing | |
| Apr 13, 2023 | Alentis Therapeutics closes USD 105 million Series C round | |
| Oct 4, 2022 | Araris Biotech Closes $24 Million Financing Round | |
| Sep 16, 2022 | French biotech Tridek-One gets €16 million booster to restore the immune balance in patients | Paris-based biotech startup Tridek-One has raised €16 million in funding to speed up its research and development of CD31 agonists to restore the immune balance. The round was led by the Swiss VC Pureos Bioventures with the participation of... |
Show more
Reviews 0
FAQ about Pureos Bioventures
What funds has Pureos Bioventures raised?
Pureos Bioventures has announced 2 funds on Parsers VC, among them a $170M fund on Sep 23, 2020.
How many startups has Pureos Bioventures invested in?
Pureos Bioventures has 1 portfolio company on Parsers VC.
What has the press written about Pureos Bioventures?
Parsers VC has collected 31 articles mentioning Pureos Bioventures, among them “Ipsen to acquire Memo Therapeutics for up to EUR 700 million” (Jul 1, 2026) and “AnaCardio's €19 Million Leap: A New Dawn for Heart Failure Treatment” (Jan 11, 2025).
Is Pureos Bioventures still active?
Yes, Pureos Bioventures is active; its latest activity on Parsers VC dates from Sep 2, 2026.